Regulatory approval
Published by the Health Service Executive. Approved
Nivolumab in combination with platinum-based chemotherapy is indicated for the neoadjuvant treatment of resectable NSCLC at high risk of recurrence in adult patients whose tumours have PD-L1 expression >= 1%.
This is written in the approval document.
Reimbursement
Incomplete Reimbursement
Nivolumab - ODMS; Chemotherapy - N/A
Citation
Therapeutic response
Precision oncology relationships for therapeutic response derived from this regulatory approval.
Organizations
Biomarkers
Cancer types
Therapies
| Organizations | Biomarkers | Cancer types | Therapies | |
|---|---|---|---|---|
| HSE (1) | PD-L1 >= 1% | Non-Small Cell Lung Cancer | Carboplatin, Nivolumab, Paclitaxel | |
| HSE (1) | PD-L1 >= 1% | Non-Small Cell Lung Cancer | Carboplatin, Nivolumab, Pemetrexed | |
| HSE (1) | PD-L1 >= 1% | Non-Small Cell Lung Cancer | Cisplatin, Gemcitabine, Nivolumab | |
| HSE (1) | PD-L1 >= 1% | Non-Small Cell Lung Cancer | Carboplatin, Gemcitabine, Nivolumab | |
| HSE (1) | PD-L1 >= 1% | Non-Small Cell Lung Cancer | Cisplatin, Nivolumab, Pemetrexed |
Contributions
| Date | Contributor | Description |
|---|---|---|
| 2024-05-01 | Health Service Executive | Indication approved for reimbursement. |
| 2024-01-16 | Van Allen lab | Adding HSE approvals for reimbursement to database |